<DOC>
	<DOCNO>NCT02656797</DOCNO>
	<brief_summary>Comparison placebo gel treatment topical liposomal amphotericin B gel treatment cutaneous leishmaniasis Leishmania species major tropica .</brief_summary>
	<brief_title>Topical Liposomal Amphotericin B Gel Treatment Cutaneous Leishmaniasis</brief_title>
	<detailed_description>Randomized , double blind , placebo control study . The study include 108 patient cutenous leishmaniasis Leishmania species major tropica , confired Polymerase Chain Reaction sample lesion . Cure rate compare patient treat Amphotericin-B 0.4 % Liposomal Gel patient treat placebo gel preparation .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Cutaneous</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<criteria>Cutenous leishmaniasis confirm PCR ( Leishmania species major tropica ) 1 5 lesion Signed informed consent Facial lesion Significant comorbidity Pregnancy breastfeed enrollment Previous treatment leishmaniasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Leishmania major</keyword>
	<keyword>Leishmania tropica</keyword>
	<keyword>Amphotericin B</keyword>
</DOC>